Gene: NALCN

259232
CLIFAHDD|CanIon|IHPRF|IHPRF1|INNFD|VGCNL1|bA430M15.1
sodium leak channel, non-selective
protein-coding
13q32.3-q33.1
Ensembl:ENSG00000102452 MIM:611549 Vega:OTTHUMG00000017295 UniprotKB:Q8IZF0
NG_053176.1
PubMed
0   ANCO-SNPs
ND|AD
3   
NA (AD)  NA (ND)   (Frontal_Cortex)
5.169e-1 (AD)  4.420e-1 (ND)

DNA Methylation

Probe Locus(GRCh37) Gene Region p-val Trait PubMed ID
cg05673756chr13:102068650NALCN7.300e-8Smoking27651444

Gene Expression in Different Tissues

Temporal and Spatial Expressions (BrainSpan)

Footnote:
SC: sub-cortical regions; SM: sensory-motor regions; FC: frontal cortex; and TP: temporal-parietal cortex
ST1: fetal (13 - 26 postconception weeks), ST2: early infancy to late childhood (4 months to 11 years), and ST3: adolescence to adulthood (13 - 23 years)
The bar shown representes average value of the expressions.

Top Co-expressed Genes in Brain-Frontal Cortex (BA9) (GTEx v7)

Top 10 positively co-expressed genes

Gene Symbol Pearson Correlation Coefficient
CLCN40.961
ADAM220.953
DNAJC60.953
MTMR70.952
KLHL420.949
ATL10.946
AP3M20.945
REPS20.944
NBEA0.944
ITFG10.943

Top 10 negatively co-expressed genes

Gene Symbol Pearson Correlation Coefficient
CSAG1-0.544
RNF135-0.536
RAB13-0.516
PDZK1IP1-0.51
EVC2-0.489
SYDE1-0.486
RUNX3-0.475
EMP3-0.474
INHBB-0.471
TGIF1-0.469

Drugs/Compounds

    There is no DrugBank record for this gene !

ID Drug Name Action PubMed
C0297902,2',3',4,4',5-hexachlorobiphenyl"[2,4,4'-trichlorobiphenyl co-treated with 2,5,2',5'-tetrachlorobiphenyl co-treated with 2,4,5,2',5'-pentachlorobiphenyl co-treated with 2,2',3',4,4',5-hexachlorobiphenyl co-treated with 2,4,5,2',4',5'-hexachlorobiphenyl co-treated with PCB 180] results in decreased expression of NALCN mRNA"25510870
C1111182',3,3',4',5-pentachloro-4-hydroxybiphenyl"2',3,3',4',5-pentachloro-4-hydroxybiphenyl results in decreased expression of NALCN mRNA"19114083
C0817662,4,4'-trichlorobiphenyl"[2,4,4'-trichlorobiphenyl co-treated with 2,5,2',5'-tetrachlorobiphenyl co-treated with 2,4,5,2',5'-pentachlorobiphenyl co-treated with 2,2',3',4,4',5-hexachlorobiphenyl co-treated with 2,4,5,2',4',5'-hexachlorobiphenyl co-treated with PCB 180] results in decreased expression of NALCN mRNA"25510870
C0140242,4,5,2',4',5'-hexachlorobiphenyl"[2,4,4'-trichlorobiphenyl co-treated with 2,5,2',5'-tetrachlorobiphenyl co-treated with 2,4,5,2',5'-pentachlorobiphenyl co-treated with 2,2',3',4,4',5-hexachlorobiphenyl co-treated with 2,4,5,2',4',5'-hexachlorobiphenyl co-treated with PCB 180] results in decreased expression of NALCN mRNA"25510870
C0098282,4,5,2',5'-pentachlorobiphenyl"[2,4,4'-trichlorobiphenyl co-treated with 2,5,2',5'-tetrachlorobiphenyl co-treated with 2,4,5,2',5'-pentachlorobiphenyl co-treated with 2,2',3',4,4',5-hexachlorobiphenyl co-treated with 2,4,5,2',4',5'-hexachlorobiphenyl co-treated with PCB 180] results in decreased expression of NALCN mRNA"25510870
C0094072,5,2',5'-tetrachlorobiphenyl"[2,4,4'-trichlorobiphenyl co-treated with 2,5,2',5'-tetrachlorobiphenyl co-treated with 2,4,5,2',5'-pentachlorobiphenyl co-treated with 2,2',3',4,4',5-hexachlorobiphenyl co-treated with 2,4,5,2',4',5'-hexachlorobiphenyl co-treated with PCB 180] results in decreased expression of NALCN mRNA"25510870
C0065512-amino-2-methyl-1-propanol2-amino-2-methyl-1-propanol results in decreased expression of NALCN mRNA25088246
D000082AcetaminophenAcetaminophen affects the expression of NALCN mRNA17562736
C006780bisphenol Abisphenol A results in decreased expression of NALCN mRNA25181051
C018475butyraldehydebutyraldehyde results in decreased expression of NALCN mRNA26079696
D003300Copper[NSC 689534 binds to Copper] which results in increased expression of NALCN mRNA20971185
D003907DexamethasoneDexamethasone inhibits the reaction [RX3 gene mutant form affects the expression of NALCN mRNA]27941970
D003993Dibutyl PhthalateDibutyl Phthalate results in increased expression of NALCN mRNA21266533
D002945Cisplatin[Cisplatin co-treated with jinfukang] results in decreased expression of NALCN mRNA27392435
D002945CisplatinCisplatin results in decreased expression of NALCN mRNA27392435
D004054DiethylstilbestrolDiethylstilbestrol results in decreased expression of NALCN mRNA17005392
D006830Hydralazine[Hydralazine co-treated with Valproic Acid] results in increased expression of NALCN mRNA17183730
C544151jinfukang[Cisplatin co-treated with jinfukang] results in decreased expression of NALCN mRNA27392435
C544151jinfukangjinfukang results in decreased expression of NALCN mRNA27392435
C561695(+)-JQ1 compound(+)-JQ1 compound results in decreased expression of NALCN mRNA26752646
C016599mono-(2-ethylhexyl)phthalatemono-(2-ethylhexyl)phthalate results in decreased expression of NALCN mRNA22401849
D009532NickelNickel results in decreased expression of NALCN mRNA24768652|2558310
C558013NSC 689534[NSC 689534 binds to Copper] which results in increased expression of NALCN mRNA20971185
C410127PCB 180"[2,4,4'-trichlorobiphenyl co-treated with 2,5,2',5'-tetrachlorobiphenyl co-treated with 2,4,5,2',5'-pentachlorobiphenyl co-treated with 2,2',3',4,4',5-hexachlorobiphenyl co-treated with 2,4,5,2',4',5'-hexachlorobiphenyl co-treated with PCB 180] results in decreased expression of NALCN mRNA"25510870
D011374ProgesteroneProgesterone results in increased expression of NALCN mRNA21795739
C005556propionaldehydepropionaldehyde results in increased expression of NALCN mRNA26079696
D011441PropylthiouracilPropylthiouracil results in decreased expression of NALCN mRNA24780913
C089730rosiglitazonerosiglitazone results in increased expression of NALCN mRNA21515302
D012969Sodium FluorideSodium Fluoride results in decreased expression of NALCN mRNA27862939
C501413tesaglitazartesaglitazar results in increased expression of NALCN mRNA21515302
C057693troglitazonetroglitazone results in decreased expression of NALCN mRNA21515302
D014635Valproic Acid[Hydralazine co-treated with Valproic Acid] results in increased expression of NALCN mRNA17183730
D014635Valproic AcidValproic Acid results in decreased methylation of NALCN gene29154799
C111237vorinostatvorinostat results in decreased expression of NALCN mRNA27188386

GO/Pathway

GO ID GO Term Qualifier Evidence PubMed
GO:0005244voltage-gated ion channel activity-IEA-  
GO:0005261cation channel activity-ISS-  
GO:0005272sodium channel activity-TAS-  
GO:0005515protein binding-IPI19575010  25416956  
GO:0022840leak channel activity-ISS-  
GO ID GO Term Qualifier Evidence PubMed
GO:0034220ion transmembrane transport-TAS-  
GO:0034765regulation of ion transmembrane transport-IEA-  
GO:0035725sodium ion transmembrane transport-ISS-  
GO:0060075regulation of resting membrane potential-ISS-  
GO:0070588calcium ion transmembrane transport-ISS-  
GO:0071805potassium ion transmembrane transport-ISS-  
GO ID GO Term Qualifier Evidence PubMed
GO:0005886plasma membrane-TAS-  
GO:0016021integral component of membrane-IEA-  
KEGG ID KEGG Term
Reactome ID Reactome Term Evidence
R-HSA-2672351Stimuli-sensing channelsTAS
R-HSA-382551Transport of small moleculesTAS
R-HSA-983712Ion channel transportTAS

Interactions (STRING v10.5, Interaction Score >= 0.400)

Publications (Co-occurrence of gene symbol strings and ANCO-Dependence terms)

PMID Title (Year) Author Journal
24904279The sodium leak channel, NALCN, in health and disease. (2014)Cochet-Bissuel MFront Cell Neurosci
24015780Family-based association analysis of alcohol dependence criteria and severity. (2014 Feb)Wetherill LAlcohol Clin Exp Res
23144319Prognostic implications of genetic variants in advanced non-small cell lung cancer: a genome-wide association study. (2013 Feb)Lee YCarcinogenesis